UK's Decentralized Manufacturing Could Be A Revolution; Mind The Risk

By Kyle Winn and Adam Walker, W2 Cleanroom Consulting

The UK has taken a bold steps. With the introduction of The Human Medicines (Amendment) (Modular Manufacture and Point of Care) Regulations 2025 (SI 2025/87), there is an exciting new prospect for medicine manufacture in the UK. Decentralized manufacture is no longer a concept discussed at conferences. It is now a defined legal pathway. This is a structural shift.

For decades, pharmaceutical manufacturing has been built around scale-up. Large, centralized facilities, long supply chains, and high-volume production runs. That model works for stable products. It struggles when therapies are personalized, unstable, or clinically time-critical.

The 2025 framework introduces a scale-out model. Manufacture can occur at or near the site of care under a licensed control site operating a hub-and-spoke network. Importantly, the sites of manufacture do not have their own manufacturing authorization; they operate as an extension of the control site’s authorization, and under the oversight of their QMS.

Truly, it's an innovative model. Whether it leads to greater patient access remains to be seen.

The Real Prize Is Patient Access

If implemented properly, decentralized manufacture could change the experience of patients in ways that were previously unrealistic.

For advanced therapies such as autologous CAR-T products, vein-to-vein time has been one of the greatest practical barriers. Patient health deteriorates while cells travel internationally and wait in line for a limited number of manufacturing slots. Moreover, cells are often shipped cryogenically preserved, presenting operational challenges. While these challenges have been overcome with the existing CAR-T therapies, there may be other products where such controls still aren’t enough to get the treatment to the patient in time.

A decentralized model, where processing occurs within a hospital environment under a licensed control site, has the potential to eliminate a lot of these challenges and allow delivery of highly complex, often bespoke medicines. The same applies to unstable or time-sensitive therapies. Products that cannot tolerate extended transport or storage could be manufactured or activated close to the patient.

There is also a credible argument around equity. A single national center of excellence does not automatically guarantee equitable access. A scale-out model allows regional sites to operate as spokes under central governance, potentially narrowing geographic disparities. On paper, this looks transformative.

Where Accountability And Governance Come In

The legislation solves one problem elegantly. It avoids the need to individually license hundreds of sites by concentrating regulatory accountability in the control site.

There is only one manufacturer’s license holder, one marketing authorization holder, and one point of ultimate accountability. It's as efficient as it is uncompromising.

The control site carries full responsibility for every spoke listed in the decentralized manufacturing master file. If contamination control fails in a remote location, the liability does not remain local. It sits centrally, intensifying governance expectations at the control site.

The control site must have:

• validated data visibility across all active spokes,
• standardised operational processes correctly deployed remotely,
• clear role definition for any local staff performing manufacturing, testing or local release, and
• robust infrastructure capable of sustaining continuous oversight.

With more interfaces, people, locations, and variables, we've described the antithesis of simplification. Thankfully, the regulation provides clarity on how it must be controlled.

Technology Will Not Compensate For Weak Systems

There is an expectation that decentralized manufacture will be technology-led, but this does not reduce the governance requirements for the control site or remote sites.

Automated manufacturing systems and modular cleanrooms are not self-governing. Without disciplined capacity modeling, realistic staffing assumptions and strong quality oversight, decentralization risks redistributing vulnerability rather than reducing it.

The control site must not only certify batches, it must certify confidence in a network it is responsible for. In order to effectively deliver this level of oversight, effective capacity models must be used in this new and developing area.

The Opportunity Is Real, But So Is The Responsibility

The UK is the first jurisdiction to implement a comprehensive decentralized manufacturing framework into law. That is significant.

If executed with discipline, this model could:

• Reduce time-to-treatment for novel therapies,
• Enable delivery of unstable or ultra-short shelf-life products,
• Improve national resilience during public health emergencies, and
• Broaden access beyond major academic centres.

However, decentralization is structured complexity. It demands operational integrity, contamination control consistency and governance resource at a scale that many organizations have not previously managed.

Decentralized manufacture will only improve patient outcomes if the pharmaceutical quality system at the control site is strong enough to carry the weight of the network. If it isn't, the model exposes weakness quickly.

About The Authors:

Kyle Winn is co-director of W2 Cleanroom Consulting Ltd, specializing in sterile pharmaceutical manufacturing operations, GMP system design, and cleanroom facility development. He supports pharmaceutical manufacturers and aseptic production facilities with cleanroom design review and validation lifecycle implementation to help organizations build inspection-ready manufacturing systems.

Adam Walker is co-director of W2 Cleanroom Consulting Ltd. and a Qualified Person specializing in pharmaceutical manufacturing and GMP quality systems. He supports pharmaceutical manufacturers and aseptic production facilities with contamination control strategy development, quality governance frameworks, and regulatory inspection readiness across the product lifecycle.